Immunology, Immunology and Allergy, General Immunology and Microbiology, Immunology and Microbiology
129
Scopus Publications
15718
Scholar Citations
59
Scholar h-index
168
Scholar i10-index
Scopus Publications
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial E. Seguí, F. Brasó-Maristany, T. Pascual, E. Sanfeliu, I. Victoria, C. Saura, C. Hierro, A. López-González, Y. Izarzugaza, E. Ciruelos, J. Gavilá, F. Racca, J.M. Cejalvo, K. Amillano, L. Paz-Ares, M. Juan, E. Felip, E. Garralda, B. González, A. Arance, J. Martín-Liberal, B. Conte, B. Walbaum, A. Indacochea, O. Castillo, P. Blasco, F. Pardo, Á. Aguirre, V. Sirenko, X. González, P. Galván, A. Vivancos, J.M. Ferrero-Cafiero, A. Mulero-Sánchez, F. Salvador, G. Villacampa, R. Mesía, A. Cervantes, A. Prat, J. Tabernero ESMO Open, 2025 BACKGROUND: Immune checkpoint inhibitors (ICIs) have transformed the treatment of solid tumors, yet responses vary across cancer types, highlighting the need for reliable pan-cancer biomarkers. Prior retrospective studies identified PD1 mRNA as a promising predictor of anti-PD1 response, but prospective validation was lacking. PATIENTS AND METHODS: The SOLTI-1904 ACROPOLI trial was a non-randomized, open-label, multicenter phase II study designed to evaluate the efficacy of anti-PD1 monotherapy in patients with advanced solid tumors and high PD1 mRNA expression (cohort 1). An exploratory cohort also enrolled PD1-low tumors from cancer types with known ICI sensitivity (cohort 2). Between April 2021 and March 2022, 1003 patients across 33 cancer types were prescreened; 10.6% were classified as PD1-high. A total of 56 PD1-high and 15 PD1-low cases were enrolled to receive spartalizumab (400 mg intravenously every 4 weeks). The primary endpoint was objective response rate (ORR) in PD1-high tumors. Cohorts 1 and 2 were closed early due to discontinuation of spartalizumab development, before reaching full accrual. RESULTS: In the PD1-cohort, which included heavily pretreated tumors (median two prior lines) across 19 histologies, the ORR was 17.9% (95% confidence interval 7.8% to 27.9%). Among patients with tissue samples collected within 12 months of treatment, the ORR increased to 33.3%. The clinical benefit rate (partial response or stable disease ≥24 weeks) was 30.4%. Responses occurred in cancers typically resistant to ICIs, including pancreatic and microsatellite-stable colorectal cancers. No new safety signals were identified. Programmed death-ligand 1 expression by immunohistochemistry was significantly associated with response, whereas exploratory analyses identified additional potential biomarkers, including B cell gene signatures and tumor proliferation markers. CONCLUSIONS: PD1 mRNA may help identify immunogenic tumors across cancer types. However, the trial's early closure and exploratory nature warrant further validation. A composite biomarker strategy integrating immune and tumor-intrinsic features may improve patient selection for ICIs.
Atypical lymphoid cells circulating in blood in COVID-19 infection: morphology, immunophenotype and prognosis value Anna Merino, Alexandru Vlagea, Angel Molina, Natalia Egri, Javier Laguna, Kevin Barrera, Laura Boldú, Andrea Acevedo, Mar Díaz-Pavón, Francesc Sibina, Francisca Bascón, Oriol Sibila, Manel Juan, José Rodellar Journal of Clinical Pathology, 2022 AimsAtypical lymphocytes circulating in blood have been reported in COVID-19 patients. This study aims to (1) analyse if patients with reactive lymphocytes (COVID-19 RL) show clinical or biological characteristics related to outcome; (2) develop an automatic system to recognise them in an objective way and (3) study their immunophenotype.MethodsClinical and laboratory findings in 36 COVID-19 patients were compared between those showing COVID-19 RL in blood (18) and those without (18). Blood samples were analysed in Advia2120i and stained with May Grünwald-Giemsa. Digital images were acquired in CellaVisionDM96. Convolutional neural networks (CNNs) were used to accurately recognise COVID-19 RL. Immunophenotypic study was performed throughflow cytometry.ResultsNeutrophils, D-dimer, procalcitonin, glomerular filtration rate and total protein values were higher in patients without COVID-19 RL (p<0.05) and four of these patients died. Haemoglobin and lymphocyte counts were higher (p<0.02) and no patients died in the group showing COVID-19 RL. COVID-19 RL showed a distinct deep blue cytoplasm with nucleus mostly in eccentric position. Through two sequential CNNs, they were automatically distinguished from normal lymphocytes and classical RL with sensitivity, specificity and overall accuracy values of 90.5%, 99.4% and 98.7%, respectively. Immunophenotypic analysis revealed COVID-19 RL are mostly activated effector memory CD4 and CD8 T cells.ConclusionWe found that COVID-19 RL are related to a better evolution and prognosis. They can be detected by morphology in the smear review, being the computerised approach proposed useful to enhance a more objective recognition. Their presence suggests an abundant production of virus-specific T cells, thus explaining the better outcome of patients showing these cells circulating in blood.
Similarities and differences between the immunopathogenesis of COVID-19-related pediatric multisystem inflammatory syndrome and Kawasaki disease Ana Esteve-Sole, Jordi Anton, Rosa Maria Pino-Ramirez, Judith Sanchez-Manubens, Victoria Fumadó, Claudia Fortuny, María Rios-Barnes, Joan Sanchez-de-Toledo, Mónica Girona-Alarcón, Juan Manuel Mosquera, Silvia Ricart, Cristian Launes, Mariona Fernández de Sevilla, Cristina Jou, Carmen Muñoz-Almagro, Eva González-Roca, Andrea Vergara, Jorge Carrillo, Manel Juan, Daniel Cuadras, Antoni Noguera-Julian, Iolanda Jordan, Laia Alsina Journal of Clinical Investigation, 2021 Multisystem inflammatory syndrome associated with the SARS-CoV-2 pandemic has recently been described in children (MIS-C), partially overlapping with Kawasaki disease (KD). We hypothesized that (a) MIS-C and prepandemic KD cytokine profiles may be unique and justify the clinical differences observed, and (b) SARS-CoV-2-specific immune complexes (ICs) may explain the immunopathology of MIS-C. Seventy-four children were included: 14 with MIS-C, 9 patients positive for SARS-CoV-2 by PCR without MIS-C (COVID), 14 with prepandemic KD, and 37 healthy controls (HCs). Thirty-four circulating cytokines were quantified in pretreatment serum or plasma samples and the presence of circulating SARS-CoV-2 ICs was evaluated in MIS-C patients. Compared with HCs, the MIS-C and KD groups showed most cytokines to be significantly elevated, with IFN-γ-induced response markers (including IFN-γ, IL-18, and IP-10) and inflammatory monocyte activation markers (including MCP-1, IL-1α, and IL-1RA) being the main triggers of inflammation. In linear discriminant analysis, MIS-C and KD profiles overlapped; however, a subgroup of MIS-C patients (MIS-Cplus) differentiated from the remaining MIS-C patients in IFN-γ, IL-18, GM-CSF, RANTES, IP-10, IL-1α, and SDF-1 and incipient signs of macrophage activation syndrome. Circulating SARS-CoV-2 ICs were not detected in MIS-C patients. Our findings suggest a major role for IFN-γ in the pathogenesis of MIS-C, which may be relevant for therapeutic management.
Car t cells targeting options in the fight against multiple myeloma Fabio NICOLINI, Sara BRAVACCINI, Massimiliano MAZZA, Alicja M. GRUSZKA, Marcella TAZZARI, Beatriz MARTÍN-ANTONIO, Manel JUAN, Toni IBRAHIM, Roberta MALTONI, Giovanni MARTINELLI, Claudio CERCHIONE Panminerva Medica, 2021 INTRODUCTION: Multiple myeloma (MM) is a hematological malignancy in which patients present with bone marrow infiltration of clonal terminally-differentiated plasma cells. Monoclonal protein in the serum and/or urine is frequently detected. Over the past decade, important progress has been made in the comprehension of disease biology and treatment personalization. Much work has been put into the development of chimeric antigen receptor (CAR) gene-modified T-cell therapy thought to be a promising therapeutic option for pluritreated patients with refractory MM. EVIDENCE ACQUISITION: We performed an analysis of clinical trials registered at the international repository clinicaltrials.gov using "CAR" OR "CAR T" AND "multiple myeloma" as search terms to understand what were the antigens targeted by CAR T strategies and what was the trade-off of their exploitation. The search retrieved a list of 103 trials that was manually filtered to eliminate follow-up and observational or not-pertinent trials. EVIDENCE SYNTHESIS: Most studies employed anti-BCMA targeting either alone (62/94; 66%), or in combination with a second target (12/94; 13%). The second target most studied was SLAMF7 (CD319) explored by 4/94 (4%) clinical trials. Other antigens investigated and described here include: CD44v6, CD38, CD138, MUC1, CD56, CD19, Igk light chain, Lewis Y, CD229 and GPRC5D. CONCLUSIONS: Targeting an appropriate antigen(s) is the key to both safety and efficacy of CAR T approaches in MM as there is dearth of tumor-specific antigens. Most antigens tested are merely enriched on MM cells. Working with tumor-enriched antigens requires careful assessment of the balance between harm (toxicity) and benefit (disease eradication) to the patient. This review provides an up-to-date overview of the avenues that are being explored.
CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies Valentín Ortíz-Maldonado, Susana Rives, Maria Castellà, Anna Alonso-Saladrigues, Daniel Benítez-Ribas, Miguel Caballero-Baños, Tycho Baumann, Joan Cid, Enric Garcia-Rey, Cristina Llanos, Montserrat Torrebadell, Neus Villamor, Eva Giné, Marina Díaz-Beyá, Laia Guardia, Mercedes Montoro, Albert Català, Anna Faura, E. Azucena González, Marta Español-Rego, Nela Klein-González, Laia Alsina, Pedro Castro, Iolanda Jordan, Sara Fernández, Federico Ramos, Guillermo Suñé, Unai Perpiñá, Josep M. Canals, Miquel Lozano, Esteve Trias, Andrea Scalise, Sara Varea, Joaquín Sáez-Peñataro, Ferran Torres, Gonzalo Calvo, Jordi Esteve, Álvaro Urbano-Ispizua, Manel Juan, Julio Delgado Molecular Therapy, 2021
Gut microbiota influence in hematological malignancies: From genesis to cure Mireia Uribe-Herranz, Nela Klein-González, Luis Gerardo Rodríguez-Lobato, Manel Juan, Carlos Fernández de Larrea International Journal of Molecular Sciences, 2021 Hematological malignancies, including multiple myeloma, lymphoma, and leukemia, are a heterogeneous group of neoplasms that affect the blood, bone marrow, and lymph nodes. They originate from uncontrolled growth of hematopoietic and lymphoid cells from different stages in their maturation/differentiation and account for 6.5% of all cancers around the world. During the last decade, it has been proven that the gut microbiota, more specifically the gastrointestinal commensal bacteria, is implicated in the genesis and progression of many diseases. The immune-modulating effects of the human microbiota extend well beyond the gut, mostly through the small molecules they produce. This review aims to summarize the current knowledge of the role of the microbiota in modulating the immune system, its role in hematological malignancies, and its influence on different therapies for these diseases, including autologous and allogeneic stem cell transplantation, chemotherapy, and chimeric antigen receptor T cells.
Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia A. Deyà-Martínez, A. Alonso-Saladrigues, A. P. García, A. Faura, M. Torrebadell, A. Vlagea, A. Català, A. Esteve-Solé, M. Juan, S. Rives, L. Alsina Bone Marrow Transplantation, 2021 CD19-CAR T-cell therapy (CART19) causes B-cell aplasia (BCA) and dysgammaglobulinemia but there is a lack of information about the degree of its secondary immunodeficiency. We conducted a prospective study in children and young adults with acute lymphoblastic leukaemia treated with CART19, analysing the kinetics of BCA and dysgammaglobulinemia during therapy, as well as the B-cell reconstitution in those with CART19 loss. Thirty-four patients were included (14 female) with a median age at CART19 infusion of 8.7 years (2.9–24.9). Median follow-up after infusion was 7.1 months (0.5–42). BCA was observed 7 days after infusion (3–8), with persistence at 24 months in 60% of patients. All patients developed a progressive decrease in IgM and IgA: 71% had undetectable IgM levels at 71 days (41–99) and 13% undetectable IgA levels at 185 days (11–308). Three of 12 patients had protective levels of IgA in saliva. In two of three patients who lost CART19, persistent B-cell dysfunction was observed. No severe infections occurred. In conclusion, BCA occurs soon after CART19 infusion, with a progressive decrease in IgM and IgA, and with less impairment of IgA, suggesting the possibility of an immune reservoir. A persistent B-cell dysfunction might persist after CART19 loss in this population.
Preclinical development of a humanized chimeric antigen receptor against B-cell maturation antigen for multiple myeloma Lorena Perez-Amill, Guillermo Suñe, Asier Antoñana-Vildosola, Maria Castella, Amer Najjar, Jaume Bonet, Narcis Fernández-Fuentes, Susana Inogés, Ascensión López, Clara Bueno, Manel Juan, Álvaro Urbano-Ispizua, Beatriz Martín-Antonio Haematologica, 2021 Multiple myeloma is a prevalent and incurable disease, despite the development of new and effective drugs. The recent development of chimeric antigen receptor (CAR)-T cell therapy has shown impressive results in the treatment of patients with relapsed or refractory hematological B cell malignancies. In the recent years, B-cell maturation antigen (BCMA) has appeared as a promising antigen to target using a variety of immuno-therapy treatments including CART cells, for MM patients. To this end, we generated clinical-grade murine CART cells directed against BCMA, named ARI2m cells. Having demonstrated its efficacy, and in an attempt to avoid the immune rejection of CART cells by the patient, the single chain variable fragment was humanized, creating ARI2h cells. ARI2h cells demonstrated comparable in vitro and in vivo efficacy to ARI2m cells, and superiority in cases of high tumor burden disease. In terms of inflammatory response, ARI2h cells showed a lower TNFα production and lower in vivo toxicity profile. Large-scale expansion of both ARI2m and ARI2h cells was efficiently conducted following Good Manufacturing Practice guidelines, obtaining the target CART cell dose required for treatment of multiple myeloma patients. Moreover, we demonstrate that soluble BCMA and BCMA released in vesicles impacts on CAR-BCMA activity. In summary, this study sets the bases for the implementation of a clinical trial (EudraCT code: 2019-001472-11) to study the efficacy of ARI2h cell treatment for multiple myeloma patients.
Severe Autoinflammatory Manifestations and Antibody Deficiency Due to Novel Hypermorphic PLCG2 Mutations Andrea Martín-Nalda, Claudia Fortuny, Lourdes Rey, Tom D. Bunney, Laia Alsina, Ana Esteve-Solé, Daniel Bull, Maria Carmen Anton, María Basagaña, Ferran Casals, Angela Deyá, Marina García-Prat, Ramon Gimeno, Manel Juan, Helios Martinez-Banaclocha, Juan J Martinez-Garcia, Anna Mensa-Vilaró, Raquel Rabionet, Nieves Martin-Begue, Francesc Rudilla, Jordi Yagüe, Xavier Estivill, Vicente García-Patos, Ramon M. Pujol, Pere Soler-Palacín, Matilda Katan, Pablo Pelegrín, Roger Colobran, Asun Vicente, Juan I. Arostegui Journal of Clinical Immunology, 2020
Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor: Experience from an academic phase i clinical trial Maria Castella, Miguel Caballero-Baños, Valentín Ortiz-Maldonado, Europa Azucena González-Navarro, Guillermo Suñé, Asier Antoñana-Vidósola, Anna Boronat, Berta Marzal, Lucía Millán, Beatriz Martín-Antonio, Joan Cid, Miquel Lozano, Enric García, Jaime Tabera, Esteve Trias, Unai Perpiña, Josep Ma Canals, Tycho Baumann, Daniel Benítez-Ribas, Elías Campo, Jordi Yagüe, Álvaro Urbano-Ispizua, Susana Rives, Julio Delgado, Manel Juan Frontiers in Immunology, 2020
Next-generation HLA typing of 382 International Histocompatibility Working Group reference B-lymphoblastoid cell lines: Report from the 17th International HLA and Immunogenetics Workshop Lisa E. Creary, Sandra G. Guerra, Winnie Chong, Colin J. Brown, Thomas R. Turner, James Robinson, Will P. Bultitude, Neema P. Mayor, Steven G.E. Marsh, Katsuyuki Saito, Kevin Lam, Jamie L. Duke, Timothy L. Mosbruger, Deborah Ferriola, Dimitrios Monos, Amanda Willis, Medhat Askar, Gottfried Fischer, Chee Loong Saw, Jiannis Ragoussis, Martin Petrek, Carles Serra-Pagés, Manel Juan, Catherine Stavropoulos-Giokas, Amalia Dinou, Reem Ameen, Salem Al Shemmari, Eric Spierings, Ketevan Gendzekhadze, Gerald P. Morris, Qiuheng Zhang, Zahra Kashi, Susan Hsu, Sridevi Gangavarapu, Kalyan C. Mallempati, Fumiko Yamamoto, Kazutoyo Osoegawa, Tamara Vayntrub, Chia-Jung Chang, John A. Hansen, Marcelo A. Fernández-Viňa Human Immunology, 2019
Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions Maria Castella, Anna Boronat, Raquel Martín-Ibáñez, Vanina Rodríguez, Guillermo Suñé, Miguel Caballero, Berta Marzal, Lorena Pérez-Amill, Beatriz Martín-Antonio, Julio Castaño, Clara Bueno, Olga Balagué, Europa Azucena González-Navarro, Carles Serra-Pages, Pablo Engel, Ramon Vilella, Daniel Benitez-Ribas, Valentín Ortiz-Maldonado, Joan Cid, Jaime Tabera, Josep M. Canals, Miquel Lozano, Tycho Baumann, Anna Vilarrodona, Esteve Trias, Elías Campo, Pablo Menendez, Álvaro Urbano-Ispizua, Jordi Yagüe, Patricia Pérez-Galán, Susana Rives, Julio Delgado, Manel Juan Molecular Therapy Methods and Clinical Development, 2019
Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial Irati Zubizarreta, Georgina Flórez-Grau, Gemma Vila, Raquel Cabezón, Carolina España, Magi Andorra, Albert Saiz, Sara Llufriu, Maria Sepulveda, Nuria Sola-Valls, Elena H. Martinez-Lapiscina, Irene Pulido-Valdeolivas, Bonaventura Casanova, Marisa Martinez Gines, Nieves Tellez, Celia Oreja-Guevara, Marta Español, Esteve Trias, Joan Cid, Manel Juan, Miquel Lozano, Yolanda Blanco, Lawrence Steinman, Daniel Benitez-Ribas, Pablo Villoslada Proceedings of the National Academy of Sciences of the United States of America, 2019
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types L. Paré, T. Pascual, E. Seguí, C. Teixidó, M. Gonzalez-Cao, P. Galván, A. Rodríguez, B. González, M. Cuatrecasas, E. Pineda, A. Torné, G. Crespo, S. Martin-Algarra, E. Pérez-Ruiz, Ò Reig, M. Viladot, C. Font, B. Adamo, M. Vidal, L. Gaba, M. Muñoz, I. Victoria, G. Ruiz, N. Viñolas, B. Mellado, J. Maurel, J. Garcia-Corbacho, M Á Molina-Vila, M. Juan, J.M. Llovet, N. Reguart, A. Arance, A. Prat Annals of Oncology, 2018
Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis Thaís Armangue, Marianna Spatola, Alexandru Vlagea, Simone Mattozzi, Marc Cárceles-Cordon, Eloy Martinez-Heras, Sara Llufriu, Jordi Muchart, María Elena Erro, Laura Abraira, German Moris, Luis Monros-Giménez, Íñigo Corral-Corral, Carmen Montejo, Manuel Toledo, Luis Bataller, Gabriela Secondi, Helena Ariño, Eugenia Martínez-Hernández, Manel Juan, Maria Angeles Marcos, Laia Alsina, Albert Saiz, Myrna R Rosenfeld, Francesc Graus, Josep Dalmau, Sergio Aguilera-Albesa, Alfonso Amado-Puentes, Antonio Arjona-Padillo, Luisa Arrabal, Izascun Arratibel, Gemma Aznar-Laín, Paula Bellas-Lamas, Teresa Bermejo, Sabas Boyero-Durán, Ana Camacho, Andrea Campo, Dulce Campos, Verónica Cantarín-Extremera, Cristóbal Carnero, David Conejo-Moreno, Marta Dapena, David Dacruz-Álvarez, Verónica Delgadillo-Chilavert, Angela Deyà, Jordi Estela-Herrero, Anna Felipe, Elisa Fernández-Cooke, Joaquín Fernández-Ramos, Claudia Fortuny, Juan C García-Monco, Teresa Gili, Verónica González-Álvarez, Robert Guerri, Sara Guillén, Antonio Hedrera-Fernández, María López, Eduardo López-Laso, María Lorenzo-Ruiz, Marcos Madruga, Ignacio Málaga-Diéguez, Itxaso Martí-Carrera, Xavier Martínez-Lacasa, Lucía Martín-Viota, Leticia Martín Gil, María-Jesús Martínez-González, Antia Moreira, María C Miranda-Herrero, Lorena Monge, Beatriz Muñoz-Cabello, Juan Navarro-Morón, Olaf Neth, Antoni Noguera-Julian, Noemí Nuñez-Enamorado, Virginia Pomar, Juan C Portillo-Cuenca, María Poyato, Luis Prieto, Luis Querol, Eloy Rodríguez-Rodríguez, Silvana Sarria-Estrada, Concepción Sierra, Pere Soler-Palacín, Víctor Soto-Insuga, Laura Toledo-Bravo, Miguel Tomás, Carmen Torres-Torres, Eulàlia Turón, Ana Zabalza Lancet Neurology, 2018
B regulatory cells: Players in pregnancy and early life Ana Esteve-Solé, Yiyi Luo, Alexandru Vlagea, Ángela Deyà-Martínez, Jordi Yagüe, Ana María Plaza-Martín, Manel Juan, Laia Alsina International Journal of Molecular Sciences, 2018
Evaluating the genetics of common variable immunodeficiency: Monogenetic model and beyond Guillem de Valles-Ibáñez, Ana Esteve-Solé, Mònica Piquer, E. Azucena González-Navarro, Jessica Hernandez-Rodriguez, Hafid Laayouni, Eva González-Roca, Ana María Plaza-Martin, Ángela Deyà-Martínez, Andrea Martín-Nalda, Mónica Martínez-Gallo, Marina García-Prat, Lucía del Pino-Molina, Ivón Cuscó, Marta Codina-Solà, Laura Batlle-Masó, Manuel Solís-Moruno, Tomàs Marquès-Bonet, Elena Bosch, Eduardo López-Granados, Juan Ignacio Aróstegui, Pere Soler-Palacín, Roger Colobran, Jordi Yagüe, Laia Alsina, Manel Juan, Ferran Casals Frontiers in Immunology, 2018
mTOR intersects antibody-inducing signals from TACI in marginal zone B cells Jordi Sintes, Maurizio Gentile, Shuling Zhang, Yolanda Garcia-Carmona, Giuliana Magri, Linda Cassis, Daniel Segura-Garzón, Alessandra Ciociola, Emilie K. Grasset, Sabrina Bascones, Laura Comerma, Marc Pybus, David Lligé, Irene Puga, Cindy Gutzeit, Bing He, Wendy DuBois, Marta Crespo, Julio Pascual, Anna Mensa, Juan Ignacio Aróstegui, Manel Juan, Jordi Yagüe, Sergi Serrano, Josep Lloreta, Eric Meffre, Michael Hahne, Charlotte Cunningham-Rundles, Beverly A. Mock, Andrea Cerutti Nature Communications, 2017
Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM) On behalf of the Spanish Melanoma Group (GEM), Maria Gonzalez-Cao, Alfonso Berrocal, Susana Puig, Niki Karachaliou, Leticia De Matos-Arruda, Joan Seoane, David Escors, Carmen Alvarez, Jose Pedro Vaque, Aleix Prat, Claudia Wellbrock, Imanol Arozarena, Ivan Marquez-Rodas, Enrique Espinosa, Migue Angel Molina, Teresa Puertolas, Manuel Juan-Otero, Rosina Malagrida, Eloisa Jantus-Lewintre, Virtudes Soriano, Ana Arance, Jose Luis Manzano, Paul Lorigan, Thomas F. Gajewski, Rafael Rosell, Salvador Martin-Algarra Annals of Translational Medicine, 2017
The inflammasome pathway in stable COPD and acute exacerbations Rosa Faner, Patricia Sobradillo, Aina Noguera, Cristina Gomez, Tamara Cruz, Alejandra López-Giraldo, Eugeni Ballester, Nestor Soler, Juan I. Arostegui, Pablo Pelegrín, Roberto Rodriguez-Roisin, Jordi Yagüe, Borja G. Cosio, Manel Juan, Alvar Agustí Erj Open Research, 2016
Clues to management of neonatally diagnosed BTK deficiency Angela Deyà‐Martínez, Ana Esteve‐Sole, Maria Teresa Giner, Juan I. Aróstegui, Estíbaliz Ruiz‐Ortiz, Jordi Yagüe, Manel Juan, Ana Maria Plaza, Laia Alsina Pediatric Allergy and Immunology, 2016
Non-Hodgkin lymphoma in pediatric patients with common variable immunodeficiency Monica Piquer Gibert, Laia Alsina, María Teresa Giner Muñoz, Ofelia Cruz Martínez, Karen Ruiz Echevarria, Olga Dominguez, Ana María Plaza Martín, Juan I. Arostegui, Guillem de Valles, Manel Juan Otero, Maria Anunciacion Martin-Mateos European Journal of Pediatrics, 2015
Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome Alejandra Martínez-Trillos, Magda Pinyol, Alba Navarro, Marta Aymerich, Pedro Jares, Manel Juan, María Rozman, Dolors Colomer, Julio Delgado, Eva Giné, Marcos González-Díaz, Jesús M. Hernández-Rivas, Enrique Colado, Consolación Rayón, Angel R. Payer, Maria José Terol, Blanca Navarro, Victor Quesada, Xosé S. Puente, Ciril Rozman, Carlos López-Otín, Elías Campo, Armando López-Guillermo, Neus Villamor Blood, 2014
Erratum: B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen (Nature Immunology (2012) 13 (170-180)) Irene Puga, Montserrat Cols, Carolina M Barra, Bing He, Linda Cassis, Maurizio Gentile, Laura Comerma, Alejo Chorny, Meimei Shan, Weifeng Xu, Giuliana Magri, Daniel M Knowles, Wayne Tam, April Chiu, James B Bussel, Sergi Serrano, José Antonio Lorente, Beatriz Bellosillo, Josep Lloreta, Nuria Juanpere, Francesc Alameda, Teresa Baró, Cristina Díaz de Heredia, Núria Torán, Albert Català, Montserrat Torrebadell, Claudia Fortuny, Victoria Cusí, Carmen Carreras, George A Diaz, J Magarian Blander, Claire-Michèle Farber, Guido Silvestri, Charlotte Cunningham-Rundles, Michaela Calvillo, Carlo Dufour, Lucia Dora Notarangelo, Vassilios Lougaris, Alessandro Plebani, Jean-Laurent Casanova, Stephanie C Ganal, Andreas Diefenbach, Juan Ignacio Aróstegui, Manel Juan, Jordi Yagüe, Nizar Mahlaoui, Jean Donadieu, Kang Chen, Andrea Cerutti Nature Immunology, 2014
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma Sílvia Beà, Rafael Valdés-Mas, Alba Navarro, Itziar Salaverria, David Martín-Garcia, Pedro Jares, Eva Giné, Magda Pinyol, Cristina Royo, Ferran Nadeu, Laura Conde, Manel Juan, Guillem Clot, Pedro Vizán, Luciano Di Croce, Diana A. Puente, Mónica López-Guerra, Alexandra Moros, Gael Roue, Marta Aymerich, Neus Villamor, Lluís Colomo, Antonio Martínez, Alexandra Valera, José I. Martín-Subero, Virginia Amador, Luis Hernández, Maria Rozman, Anna Enjuanes, Pilar Forcada, Ana Muntañola, Elena M. Hartmann, María J. Calasanz, Andreas Rosenwald, German Ott, Jesús M. Hernández-Rivas, Wolfram Klapper, Reiner Siebert, Adrian Wiestner, Wyndham H. Wilson, Dolors Colomer, Armando López-Guillermo, Carlos López-Otín, Xose S. Puente, Elías Campo Proceedings of the National Academy of Sciences of the United States of America, 2013
B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen Irene Puga, Montserrat Cols, Carolina M Barra, Bing He, Linda Cassis, Maurizio Gentile, Laura Comerma, Alejo Chorny, Meimei Shan, Weifeng Xu, Giuliana Magri, Daniel M Knowles, Wayne Tam, April Chiu, James B Bussel, Sergi Serrano, José Antonio Lorente, Beatriz Bellosillo, Josep Lloreta, Nuria Juanpere, Francesc Alameda, Teresa Baró, Cristina Díaz de Heredia, Núria Torán, Albert Català, Montserrat Torrebadell, Claudia Fortuny, Victoria Cusí, Carmen Carreras, George A Diaz, J Magarian Blander, Claire-Michèle Farber, Guido Silvestri, Charlotte Cunningham-Rundles, Michaela Calvillo, Carlo Dufour, Lucia Dora Notarangelo, Vassilios Lougaris, Alessandro Plebani, Jean-Laurent Casanova, Stephanie C Ganal, Andreas Diefenbach, Juan Ignacio Aróstegui, Manel Juan, Jordi Yagüe, Nizar Mahlaoui, Jean Donadieu, Kang Chen, Andrea Cerutti Nature Immunology, 2012
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia Xose S. Puente, Magda Pinyol, Víctor Quesada, Laura Conde, Gonzalo R. Ordóñez, Neus Villamor, Georgia Escaramis, Pedro Jares, Sílvia Beà, Marcos González-Díaz, Laia Bassaganyas, Tycho Baumann, Manel Juan, Mónica López-Guerra, Dolors Colomer, José M. C. Tubío, Cristina López, Alba Navarro, Cristian Tornador, Marta Aymerich, María Rozman, Jesús M. Hernández, Diana A. Puente, José M. P. Freije, Gloria Velasco, Ana Gutiérrez-Fernández, Dolors Costa, Anna Carrió, Sara Guijarro, Anna Enjuanes, Lluís Hernández, Jordi Yagüe, Pilar Nicolás, Carlos M. Romeo-Casabona, Heinz Himmelbauer, Ester Castillo, Juliane C. Dohm, Silvia de Sanjosé, Miguel A. Piris, Enrique de Alava, Jesús San Miguel, Romina Royo, Josep L. Gelpí, David Torrents, Modesto Orozco, David G. Pisano, Alfonso Valencia, Roderic Guigó, Mónica Bayés, Simon Heath, Marta Gut, Peter Klatt, John Marshall, Keiran Raine, Lucy A. Stebbings, P. Andrew Futreal, Michael R. Stratton, Peter J. Campbell, Ivo Gut, Armando López-Guillermo, Xavier Estivill, Emili Montserrat, Carlos López-Otín, Elías Campo Nature, 2011
LTBP2 and CYP1B1 mutations and associated ocular phenotypes in the Roma/Gypsy founder population Dimitar N Azmanov, Stanislava Dimitrova, Laura Florez, Sylvia Cherninkova, Dragomir Draganov, Bharti Morar, Rosmawati Saat, Manel Juan, Juan I Arostegui, Sriparna Ganguly, Himla Soodyall, Subhabrata Chakrabarti, Harish Padh, Miguel A López-Nevot, Violeta Chernodrinska, Botio Anguelov, Partha Majumder, Lyudmila Angelova, Radka Kaneva, David A Mackey, Ivailo Tournev, Luba Kalaydjieva European Journal of Human Genetics, 2011
Moléculas de adhesión en las interacciones entre los leucocitos, el endotelio y la matriz extracelular (I). Estructura, distribución y función biológica Medicina Clinica, 1997
Existence of a soluble form of CD50 (intercellular adhesion molecule-3) produced upon human lymphocyte activation: Present in normal human serum and levels are increased in the serum of systemic lupus erythematosus patients Journal of Immunology, 1995
CD50 (intercellular adhesion molecule 3) stimulation induces calcium mobilization and tyrosine phosphorylation through p59fyn and p56lck in jurkat T cell line Journal of Experimental Medicine, 1994
CDw50 and ICAM‐3: Two names for the same molecule Manel Juan, Ramon Vilella, Jordi Mila, Jordi Yagüe, Agusti Miralles, Kerry S. Campbell, R. Joachim Friedrich, John Cambier, Jordi Vives, Antonin R. De Fougerolles, Timothy A. Springer European Journal of Immunology, 1993
Age-Related Patterns of Type II Interferon Immunity: Implications for Intramacrophagic Infections and MSMD Diagnosis During Childhood Y Luo, G Argüello, D Acevedo, C Jou, A Codina, J Márquez, A Vlagea, ... Journal of Clinical Immunology 46 (1), 13 , 2026 2026
Academic BCMA CAR-T (ARI0002h) achieves MRD-negative remission with sBCMA biomarker response in relapsed POEMS syndrome after double ASCT V Torrecillas-Mayayo, A Oliver-Caldes, N Martínez-Cibrian, N Albiol, ... Annals of Hematology , 2026 2026
Varnimcabtagene autoleucel (ARI‐0001) in relapsed or refractory mantle cell lymphoma N Albiol, N Martínez‐Cibrián, AI Pérez, S Navarro‐Velázquez, G Muzzi, ... HemaSphere 10 (5) , 2026 2026
Single-cell multiomics reveals regulatory mechanisms of CAR T-cell persistence and dysfunction in multiple myeloma L Jordana-Urriza, G Serrano, S Camara-Peña, ME Calleja-Cervantes, ... Blood Neoplasia 3 (2), 100203 , 2026 2026 Citations: 1
IgD from atypical-like memory B cells and plasma cells targets commensal and environmental antigens R Tachó-Piñot, H Bashour, M Filipska, C Corral-Vazquez, M Guzman, ... Journal of Experimental Medicine 223 (5), e20251752 , 2026 2026
425P Final analysis of the phase Ib-II trial of dendritic cell vaccination plus atezolizumab in ES-SCLC (VENEZOLUNG) MG Cao, MTM Bueno, N Reguart, M Sistere, A Meyerhans, AA Hernandez, ... ESMO Open 11 , 2026 2026
Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domain O Cardus, JM Pujol, A de Daniel, DF Moreno, TGM Oliveira, AM Battram, ... Journal for Immunotherapy of Cancer 14 (3), e011864 , 2026 2026
Unveiling Immune Surveillance in Lynch Syndrome: Insights from T-Cell Population Characterization C Bayo, J Andres, G Florez-Grau, L Rivero, M Daca, M Pellise, R Moreira, ... INTERNATIONAL JOURNAL OF CANCER 158 , 2026 2026
Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO) T Pascual, M Vidal, JM Cejalvo, E Vega, E Sanfeliu, G Villacampa, ... Nature Communications , 2026 2026 Citations: 1
Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial V Ortiz-Maldonado, N Martínez-Cibrian, L Alserawan, M Español-Rego, ... The Lancet Haematology , 2026 2026 Citations: 1
Current capacity and gaps in viral vector manufacturing: a survey of centers associated with CTIWP of EBMT, NXTGEN-hightech, DARE-NL, T2EVOLVE, and GoCART coalition G Ramesh, Z Sebestyen, AK Deshantri, S Punt, E Martinez Sanchez, ... Bone marrow transplantation 61 (2), 245-248 , 2026 2026
High specificity of engineered T cells with third generation CAR (CD28-4-1BB-CD3-ζ) based on J Gallego-Valle¹, VA Pérez-Fernández¹, J Rosales-Magallares¹, ... Unveiling the Next Generation of Cancer Immunity & Immunotherapy , 2026 2026
P-1374. Immunological Evaluation of Individuals with Multidrug-Resistant Tuberculosis in Callao, Peru DM Henson, Y Luo, N Egri, M Zavaleta, D Cuadras, M Juan, ... Open Forum Infectious Diseases 13 (Suppl 1), ofaf695. 1561 , 2026 2026
Context-dependent tonic signaling shapes the performance and manufacturability of a 4-1BB-based HER2 CAR-T cell therapy L Angelats, B Marzal, A Rodriguez-Garcia, M Español-Rego, ... bioRxiv, 2026.05. 11.724226 , 2026 2026
TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse model A Oliver-Caldes, J Mañe Pujol, AM Battram, L Perez-Amill, M Bachiller, ... Oncoimmunology 14 (1), 2529632 , 2025 2025 Citations: 3
Discovery of a pan anti-SARS-CoV-2 monoclonal antibody with highly efficient infected cell killing capacity for novel immunotherapeutic approaches D Abba Moussa, M Vazquez, C Chable-Bessia, V Roux-Portalez, ... Emerging microbes & infections 14 (1), 2432345 , 2025 2025 Citations: 5
Specific Instability of HLA-A* 03: 01 Expression in HEK-293 Cells M Area-Navarro, A Pastor-Moreno, E Scholz, A Cerqueira, ... International journal of molecular sciences 26 (23), 11357 , 2025 2025 Citations: 1
MONITORING SPECIFIC T-CELL RESPONSE TO VZV POST-VACCINATION IN HEMATOPOIETIC TRASPLANT RECIPIENTS: EXPERIENCE FROM A SINGLE CENTER TO GUIDE PROPHYLAXIS DISCONTINUATION N Egri, Y Heredia, M Aldea, J Manuel Torres, A Guardia, ... BONE MARROW TRANSPLANTATION 60, 638-639 , 2025 2025
EXPANDING CAR T-CELL THERAPY BOUNDARIES: DEVELOPING A MIXED OUTPATIENT-AT HOME MODEL BM Munoz, A Martinez-Roca, N Ballestar, C Gallego, A Estanyol, ... BONE MARROW TRANSPLANTATION 60, 300-301 , 2025 2025
Adoptive transfer of NK cells engineered with a CD5-based chimeric antigen receptor (SRCD5CAR) to treat invasive fungal infections M Velasco-de-Andrés, C Català, L Carrillo-Serradell, V Planells-Romeo, ... Molecular Therapy 33 (11), 5442-5452 , 2025 2025 Citations: 6
MOST CITED SCHOLAR PUBLICATIONS
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia XS Puente, M Pinyol, V Quesada, L Conde, GR Ordóñez, N Villamor, ... Nature 475 (7354), 101-105 , 2011 2011 Citations: 2046
Pyogenic bacterial infections in humans with MyD88 deficiency H Von Bernuth, C Picard, Z Jin, R Pankla, H Xiao, CL Ku, M Chrabieh, ... Science 321 (5889), 691-696 , 2008 2008 Citations: 980
B cell–helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen I Puga, M Cols, CM Barra, B He, L Cassis, M Gentile, L Comerma, ... Nature immunology 13 (2), 170-180 , 2012 2012 Citations: 931
Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis T Armangue, M Spatola, A Vlagea, S Mattozzi, M Cárceles-Cordon, ... The Lancet Neurology 17 (9), 760-772 , 2018 2018 Citations: 748
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma S Beà, R Valdés-Mas, A Navarro, I Salaverria, D Martín-Garcia, P Jares, ... Proceedings of the National Academy of Sciences 110 (45), 18250-18255 , 2013 2013 Citations: 673
Thyroid autoimmune disease: demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal … MP Armengol, M Juan, A Lucas-Martín, MT Fernández-Figueras, ... The American journal of pathology 159 (3), 861-873 , 2001 2001 Citations: 373
Innate lymphoid cells integrate stromal and immunological signals to enhance antibody production by splenic marginal zone B cells G Magri, M Miyajima, S Bascones, A Mortha, I Puga, L Cassis, CM Barra, ... Nature immunology 15 (4), 354-364 , 2014 2014 Citations: 338
Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics C Picado, JC Fernandez-Morata, M Juan, J Roca-Ferrer, M Fuentes, ... American Journal of Respiratory and Critical Care Medicine 160 (1), 291-296 , 1999 1999 Citations: 306
Cellular and humoral response after MRNA‐1273 SARS‐CoV‐2 vaccine in kidney transplant recipients D Cucchiari, N Egri, M Bodro, S Herrera, J Del Risco‐Zevallos, ... American Journal of Transplantation 21 (8), 2727-2739 , 2021 2021 Citations: 273
Lipid transfer protein syndrome: clinical pattern, cofactor effect and profile of molecular sensitization to plant‐foods and pollens M Pascal, R Muñoz‐Cano, Z Reina, A Palacín, R Vilella, C Picado, ... Clinical & Experimental Allergy 42 (10), 1529-1539 , 2012 2012 Citations: 272
Fibronectin upregulates gelatinase B (MMP-9) and induces coordinated expression of gelatinase A (MMP-2) and its activator MT1-MMP (MMP-14) by human T lymphocyte cell lines. A … J Esparza, C Vilardell, J Calvo, M Juan, J Vives, A Urbano-Márquez, ... Blood, The Journal of the American Society of Hematology 94 (8), 2754-2766 , 1999 1999 Citations: 272
Transcription of a broad range of self-antigens in human thymus suggests a role for central mechanisms in tolerance toward peripheral antigens M Sospedra, X Ferrer-Francesch, O Domínguez, M Juan, M Foz-Sala, ... The Journal of Immunology 161 (11), 5918-5929 , 1998 1998 Citations: 227
CAR-T cell therapy for cancer: current challenges and future directions I Zugasti, L Espinosa-Aroca, K Fidyt, V Mulens-Arias, M Diaz-Beya, ... Signal transduction and targeted therapy 10 (1), 210 , 2025 2025 Citations: 219
Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial I Zubizarreta, G Flórez-Grau, G Vila, R Cabezón, C España, M Andorra, ... Proceedings of the National Academy of Sciences 116 (17), 8463-8470 , 2019 2019 Citations: 197
CART19-BE-01: a multicenter trial of ARI-0001 cell therapy in patients with CD19+ relapsed/refractory malignancies V Ortíz-Maldonado, S Rives, M Castellà, A Alonso-Saladrigues, ... Molecular Therapy 29 (2), 636-644 , 2021 2021 Citations: 186
Evaluating the genetics of common variable immunodeficiency: monogenetic model and beyond G de Valles-Ibáñez, A Esteve-Sole, M Piquer, EA González-Navarro, ... Frontiers in Immunology 9, 636 , 2018 2018 Citations: 182
Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor: experience from an academic phase I clinical trial M Castella, M Caballero-Baños, V Ortiz-Maldonado, ... Frontiers in immunology 11, 482 , 2020 2020 Citations: 181
Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome A Martínez-Trillos, M Pinyol, A Navarro, M Aymerich, P Jares, M Juan, ... Blood, The Journal of the American Society of Hematology 123 (24), 3790-3796 , 2014 2014 Citations: 171
Expression of the human glucocorticoid receptor α and β isoforms in human respiratory epithelial cells and their regulation by dexamethasone L Pujols, J Mullol, M Pérez, J Roca-Ferrer, M Juan, A Xaubet, ... American journal of respiratory cell and molecular biology 24 (1), 49-57 , 2001 2001 Citations: 165
Development of a novel anti-CD19 chimeric antigen receptor: a paradigm for an affordable CAR T cell production at academic institutions M Castella, A Boronat, R Martín-Ibáñez, V Rodríguez, G Suñé, ... Molecular Therapy Methods & Clinical Development 12, 134-144 , 2019 2019 Citations: 162
